Peter Sand to Prospective Studies
This is a "connection" page, showing publications Peter Sand has written about Prospective Studies.
Connection Strength
0.679
-
Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study. Urology. 2021 11; 157:71-78.
Score: 0.108
-
A review of the impact of pregnancy and childbirth on pelvic floor function as assessed by objective measurement techniques. Int Urogynecol J. 2018 Mar; 29(3):327-338.
Score: 0.086
-
A multicenter, prospective trial to evaluate mesh-augmented sacrospinous hysteropexy for uterovaginal prolapse. Int Urogynecol J. 2015 May; 26(5):743-8.
Score: 0.069
-
A prospective randomized trial using solvent dehydrated fascia lata for the prevention of recurrent anterior vaginal wall prolapse. Am J Obstet Gynecol. 2005 May; 192(5):1649-54.
Score: 0.036
-
A prospective, randomized trial comparing intravesical dimethyl sulfoxide (DMSO) to bupivacaine, triamcinolone, and heparin (BTH), for newly diagnosed interstitial cystitis/painful bladder syndrome (IC/PBS). Neurourol Urodyn. 2023 03; 42(3):615-622.
Score: 0.030
-
Transvaginal Mesh Compared With Native Tissue Repair for Pelvic Organ Prolapse. Obstet Gynecol. 2022 06 01; 139(6):975-985.
Score: 0.029
-
Comparison of microtransducer and fiberoptic catheters for urodynamic studies. Obstet Gynecol. 2001 Aug; 98(2):253-7.
Score: 0.027
-
Prospective randomized trial of polyglactin 910 mesh to prevent recurrence of cystoceles and rectoceles. Am J Obstet Gynecol. 2001 Jun; 184(7):1357-62; discussion 1362-4.
Score: 0.027
-
A prospective randomized study comparing modified Burch retropubic urethropexy and suburethral sling for treatment of genuine stress incontinence with low-pressure urethra. Am J Obstet Gynecol. 2000 Jan; 182(1 Pt 1):30-4.
Score: 0.025
-
Cognitive changes in women starting anticholinergic medications for overactive bladder: a prospective study. Int Urogynecol J. 2020 Dec; 31(12):2653-2660.
Score: 0.024
-
A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome. Urology. 2019 Sep; 131:77-82.
Score: 0.024
-
Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence. J Urol. 2019 05; 201(5):967-972.
Score: 0.023
-
Effect of a urinary control insert on quality of life in incontinent women. Int Urogynecol J Pelvic Floor Dysfunct. 1999; 10(2):100-5.
Score: 0.023
-
Pelvic floor electrical stimulation for genuine stress incontinence: who will benefit and when? Int Urogynecol J Pelvic Floor Dysfunct. 1998; 9(5):265-70.
Score: 0.021
-
Pelvic floor electrical stimulation in the treatment of genuine stress incontinence: a multicenter, placebo-controlled trial. Am J Obstet Gynecol. 1995 Jul; 173(1):72-9.
Score: 0.018
-
Simple standing incremental cystometry as a screening method for detrusor instability. Obstet Gynecol. 1991 Mar; 77(3):453-7.
Score: 0.013
-
Cryosurgery versus dilation and massage for the treatment of recurrent urethral syndrome. J Reprod Med. 1989 Aug; 34(8):499-504.
Score: 0.012
-
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008 Mar; 71(3):449-54.
Score: 0.011
-
Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology. 2007 May; 69(5):876-80.
Score: 0.010
-
Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol. 2007; 39(4):1069-77.
Score: 0.010
-
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006 Nov; 28(11):1935-46.
Score: 0.010
-
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003 Jun; 78(6):687-95.
Score: 0.008
-
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001 Apr; 76(4):358-63.
Score: 0.007
-
Update on extracorporeal magnetic innervation (EXMI) therapy for stress urinary incontinence. Urology. 2000 Dec 04; 56(6 Suppl 1):82-6.
Score: 0.007
-
Extracorporeal magnetic innervation therapy for stress urinary incontinence. Urology. 1999 Jun; 53(6):1108-11.
Score: 0.006
-
Pelvic floor electrical stimulation for the treatment of urge and mixed urinary incontinence in women. Urology. 1997 Dec; 50(6):934-40.
Score: 0.005
-
Effectiveness of a urinary control insert in the management of stress urinary incontinence: early results of a multicenter study. Urology. 1996 May; 47(5):629-36.
Score: 0.005
-
Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology. 1996 Jan; 21(1):25-31.
Score: 0.005